NCT00983996已完成1 期
Single-Dose Fasting In Vivo Bioequivalence Study of Alendronate Sodium Tablets (10 mg; Mylan) and Fosamax Tablets (10 mg; Merck) in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 112
- 试验地点
- 1
- 主要终点
- Bioequivalence
研究概览
简要总结
The objective of this study is to investigate the bioequivalence of Mylan's alendronate sodium 10 mg tablets to Merck's Fosamax 10 mg tablets following a single, oral 40 mg (4 x 10 mg) dose administration under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •healthy, adult subjects, 18 years and older
- •able to swallow medication
排除标准
- •institutionalized subjects
- •history of any significant disease
- •use of any prescription or OTC medications within 14 days of start of study
- •received any investigational products within 30 days prior to start of study
研究组 & 干预措施
1
Experimental
Alendronate Sodium Tablets, 10 mg
干预措施: Alendronate Sodium Tablets, 10 mg (Drug)
2
Active Comparator
Fosamax Tablets, 10 mg
干预措施: Fosamax Tablets, 10 mg (Drug)
结局指标
主要结局
Bioequivalence
时间窗: urine collection up to 36 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Fasting Study of Alendronate Sodium Tablets (70 mg) and Fosamax Tablets (70 mg)HealthyNCT01012934Mylan Pharmaceuticals Inc110
已完成
1 期
Fasting Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mgHealthyNCT00650364Mylan Pharmaceuticals Inc38
已完成
1 期
Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mgHealthyNCT00648024Mylan Pharmaceuticals Inc47
已完成
1 期
Fasting Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mgHealthyNCT00648362Mylan Pharmaceuticals Inc40
已完成
1 期
Fasting Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mgHealthyNCT00649363Mylan Pharmaceuticals Inc28